Genzyme welcomes new Health Canada drug rules on rare diseases
Biotech company Genzyme Canada is applauding a move by Ottawa to speed up approval and access to orphan drugs for patients with rare diseases, but new regulations will determine the size of any new investments at its growing Mississauga plant.
Karen K. Ho 